Analyzing Genocea Biosciences (GNCA) and Its Peers

Genocea Biosciences (NASDAQ: GNCA) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Genocea Biosciences to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings for Genocea Biosciences and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genocea Biosciences 0 2 3 0 2.60
Genocea Biosciences Competitors 565 2470 6681 134 2.65

Genocea Biosciences currently has a consensus price target of $7.38, suggesting a potential upside of 558.48%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.46%. Given Genocea Biosciences’ higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than its rivals.

Volatility and Risk

Genocea Biosciences has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Genocea Biosciences’ rivals have a beta of 1.50, suggesting that their average stock price is 50% more volatile than the S&P 500.


This table compares Genocea Biosciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genocea Biosciences N/A -244.38% -126.44%
Genocea Biosciences Competitors -4,607.57% -480.30% -43.17%

Earnings and Valuation

This table compares Genocea Biosciences and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Genocea Biosciences $230,000.00 -$49.57 million -0.52
Genocea Biosciences Competitors $217.40 million -$39.57 million -16.79

Genocea Biosciences’ rivals have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

34.7% of Genocea Biosciences shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.7% of Genocea Biosciences shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Genocea Biosciences rivals beat Genocea Biosciences on 8 of the 13 factors compared.

About Genocea Biosciences

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.

What are top analysts saying about Genocea Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genocea Biosciences and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit